ATE476978T1 - Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns - Google Patents

Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Info

Publication number: ATE476978T1
Authority: AT; Austria
Prior art keywords: brain; glucose utilization; nervous system; central nervous; agents
Prior art date: 1998-12-17

Application number

AT99966359T

Other languages

English (en)

Inventor

Daniel G Chain

Mike Cawthorne

Original Assignee

Mindset Biopharmaceuticals Usa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-17

Filing date

1999-12-17

Publication date

2010-08-15

1999-12-17 Application filed by Mindset Biopharmaceuticals Usa filed Critical Mindset Biopharmaceuticals Usa

2010-08-15 Application granted granted Critical

2010-08-15 Publication of ATE476978T1 publication Critical patent/ATE476978T1/de

Links

210000004556 brain Anatomy 0.000 title abstract 5
206010022489 Insulin Resistance Diseases 0.000 title 1
230000003923 mental ability Effects 0.000 title 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
239000003795 chemical substances by application Substances 0.000 abstract 4
239000008103 glucose Substances 0.000 abstract 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
210000003169 central nervous system Anatomy 0.000 abstract 3
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
102000000536 PPAR gamma Human genes 0.000 abstract 2
108010016731 PPAR gamma Proteins 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
208000000044 Amnesia Diseases 0.000 abstract 1
206010012289 Dementia Diseases 0.000 abstract 1
229940122355 Insulin sensitizer Drugs 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
229940123464 Thiazolidinedione Drugs 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000002015 acyclic group Chemical group 0.000 abstract 1
230000008499 blood brain barrier function Effects 0.000 abstract 1
210000001218 blood-brain barrier Anatomy 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000006984 memory degeneration Effects 0.000 abstract 1
208000023060 memory loss Diseases 0.000 abstract 1
229960005095 pioglitazone Drugs 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
108091006084 receptor activators Proteins 0.000 abstract 1
150000001467 thiazolidinediones Chemical class 0.000 abstract 1
-1 troglitazone Chemical class 0.000 abstract 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 abstract 1
229960001641 troglitazone Drugs 0.000 abstract 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F42—AMMUNITION; BLASTING
- F42C—AMMUNITION FUZES; ARMING OR SAFETY MEANS THEREFOR
- F42C15/00—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges
- F42C15/24—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means
- F42C15/26—Arming-means in fuzes; Safety means for preventing premature detonation of fuzes or charges wherein the safety or arming action is effected by inertia means using centrifugal force

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)

AT99966359T 1998-12-17 1999-12-17 Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns ATE476978T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11266998P	1998-12-17	1998-12-17
US12225899P	1999-02-24	1999-02-24
PCT/US1999/030066 WO2000035437A2 (en)	1998-12-17	1999-12-17	Improving mental performance by increasing brain insulin sensitivity

Publications (1)

Publication Number	Publication Date
ATE476978T1 true ATE476978T1 (de)	2010-08-15

Family

ID=26810226

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99966359T ATE476978T1 (de)	1998-12-17	1999-12-17	Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns

Country Status (8)

Country	Link
EP (1)	EP1140081B1 (de)
JP (1)	JP2002532416A (de)
AT (1)	ATE476978T1 (de)
AU (3)	AU2192000A (de)
CA (1)	CA2355645A1 (de)
DE (1)	DE69942672D1 (de)
IL (2)	IL143768A0 (de)
WO (1)	WO2000035437A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0030845D0 (en) *	2000-12-18	2001-01-31	Smithkline Beecham Plc	Novel treatment
JP4452899B2 (ja)	2001-12-13	2010-04-21	味の素株式会社	新規フェニルアラニン誘導体
US6716842B2 (en)	2002-04-05	2004-04-06	Warner-Lambert Company, Llc	Antidiabetic agents
KR20080058413A (ko) *	2005-09-22	2008-06-25	에스비 팜코 푸에르토 리코 인크.	Ａｐｏｅ4 음성 환자에서의 인지 기능의 개선을 위한ｐｐａｒ-감마 작동제
EP2162127A1 (de) *	2007-05-24	2010-03-17	SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.	Zusammensetzung zur prävention einer unerwünschten wirkung durch verwendung von ppar-gamma-agonisten
WO2010068750A2 (en) *	2008-12-11	2010-06-17	Board Of Trustees Of Leland Stanford Junior University	Compositons and method for treatment of mood and cognitive impairments
JP2013530170A (ja) *	2010-06-16	2013-07-25	シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ	神経組織における神経発生を増大させるための方法における使用のためのアセチル−カルニチン
JP6735224B2 (ja)	2016-01-28	2020-08-05	花王株式会社	アストロサイトのグルコース代謝活性化剤
US12274703B2 (en)	2017-12-21	2025-04-15	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising a dementia
US12310967B2 (en)	2017-12-21	2025-05-27	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
WO2020132378A2 (en)	2018-12-22	2020-06-25	Gliapharm Sa	Compositions and methods of treatment for neurological disorders comprising depression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4540564A (en) *	1982-05-18	1985-09-10	University Of Florida	Brain-specific drug delivery
US5039794A (en) *	1986-09-19	1991-08-13	Otsuka Pharmaceutical Co., Ltd.	Tumor egress factor and processes for producing the same
IT1260155B (it) *	1992-08-03	1996-03-28	Fidia Spa	Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
GB9604242D0 (en) *	1996-02-28	1996-05-01	Glaxo Wellcome Inc	Chemical compounds
CN1280574A (zh) *	1997-10-27	2001-01-17	雷迪研究基金会	新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
AU1887999A (en) *	1998-01-29	1999-08-16	Dr. Reddy's Research Foundation	Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ504106A (en) *	1998-05-27	2003-02-28	Dr	Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
GB9822473D0 (en) *	1998-10-16	1998-12-09	Glaxo Group Ltd	Chemical compounds
WO2000023451A1 (en) *	1998-10-21	2000-04-27	Novo Nordisk A/S	New compounds, their preparation and use
AU6325599A (en) *	1998-10-21	2000-05-08	Dr. Reddy's Research Foundation	New compounds, their preparation and use
WO2000023415A1 (en) *	1998-10-21	2000-04-27	Novo Nordisk A/S	New compounds, their preparation and use
EP1123269A1 (de) *	1998-10-21	2001-08-16	Novo Nordisk A/S	Neuartige verbindungen, ihre herstellung und ihre verwendung
JP2002527502A (ja) *	1998-10-21	2002-08-27	ノボノルディスクアクティーゼルスカブ	新規化合物、それらの調製及び使用
US6028088A (en) *	1998-10-30	2000-02-22	The University Of Mississippi	Flavonoid derivatives
US6191154B1 (en) *	1998-11-27	2001-02-20	Case Western Reserve University	Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

1999
- 1999-12-17 JP JP2000587758A patent/JP2002532416A/ja active Pending
- 1999-12-17 WO PCT/US1999/030066 patent/WO2000035437A2/en not_active Ceased
- 1999-12-17 AT AT99966359T patent/ATE476978T1/de not_active IP Right Cessation
- 1999-12-17 IL IL14376899A patent/IL143768A0/xx active IP Right Grant
- 1999-12-17 CA CA002355645A patent/CA2355645A1/en not_active Abandoned
- 1999-12-17 EP EP99966359A patent/EP1140081B1/de not_active Expired - Lifetime
- 1999-12-17 DE DE69942672T patent/DE69942672D1/de not_active Expired - Lifetime
- 1999-12-17 AU AU21920/00A patent/AU2192000A/en not_active Abandoned
2001
- 2001-06-14 IL IL143768A patent/IL143768A/en not_active IP Right Cessation
2005
- 2005-03-23 AU AU2005201243A patent/AU2005201243A1/en not_active Abandoned
2009
- 2009-01-23 AU AU2009200266A patent/AU2009200266A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2002532416A (ja)	2002-10-02
AU2005201243A1 (en)	2005-04-21
DE69942672D1 (de)	2010-09-23
IL143768A (en)	2008-04-13
AU2009200266A1 (en)	2009-02-19
EP1140081A2 (de)	2001-10-10
IL143768A0 (en)	2002-04-21
EP1140081B1 (de)	2010-08-11
AU2192000A (en)	2000-07-03
WO2000035437A3 (en)	2000-11-09
WO2000035437A2 (en)	2000-06-22
CA2355645A1 (en)	2000-06-22

Similar Documents

Publication	Publication Date	Title
Tarsy et al.	1974	Physostigmine in choreiform movement disorders
ATE476978T1 (de)	2010-08-15	Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
HUP0002373A2 (hu)	2000-10-28	Glükagon antagonisták/inverz agonisták és ezeket tartalmazó gyógyászati készítmények
DE69930739D1 (de)	2006-05-18	Transdermale verwendung von sekretin zur behandlung von autismus
DE3687501D1 (de)	1993-02-25	Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eines arneimittels zur behandlung von komplikationen bei diabetes mellitus.
ATE202076T1 (de)	2001-06-15	Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
DE69519099D1 (de)	2000-11-16	Aromatische aminoether als schmerzlindernde mittel
ATE244220T1 (de)	2003-07-15	Neue heterocyclische verbindungen, verfahren zu deren herstellung sowie medizinische verwendung
RU93055137A (ru)	1996-05-20	Гетероцикло-циклические производные аминов, способ получения, промежуточные соединения, фармацевтическая композиция, способ лечения
SE8105561L (sv)	1982-03-23	Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
Boller et al.	1989	Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results
ATE182879T1 (de)	1999-08-15	Neuartig substituierte dtpa-derivate, deren metallkomplexe, diese komplexe enthaltende pharmazeutische mittel, deren verwendung in der diagnostik und therapie, sowie verfahren zur herstellung der komplexe und mittel
Murphy et al.	1974	Diphenylhydantoin-lnduced Asterixis: A Clinical Study
Knezevic et al.	1984	Neuroleptic malignant syndrome
EP0305277A3 (de)	1991-03-06	Verwendung von 2-Amino-6-trifluormethoxybenzthiazol zur Herstellung eines Arzneimittels zur Behandlung von Schlafstörungen und Depressionen
Davidoff et al.	1978	Enhancement of the mitochondrial Ca2+ uptake rate by phenethylbiguanide and other organic cations with hypoglycemic activity
KR870007937A (ko)	1987-09-23	2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
Troupin et al.	1997	Felbamate: therapeutic range and other kinetic information
KR880009944A (ko)	1988-10-06	피페라진 카르복실산, 그의 제조방법 및 그를 함유하는 약학적 조성물
Cotzias	1969	L-Dopa in Parkinson's disease
Cahn et al.	1957	Observations on the Clinical Effects of a new Tranquillizing Agent in Psychotic Conditions
Sannita et al.	1980	EEG effects and plasma concentrations of phenobarbital in volunteers
CA2411418A1 (en)	2002-12-06	Hydroxyformamidine derivatives and medicines containing the same
Dawson et al.	1989	Cardiac dysrhythmia with the use of clonidine in explosive disorder
EP0255704A3 (de)	1988-10-05	Pyridazinon-Derivate, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel

Legal Events

Date	Code	Title	Description
2011-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties